Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 20 Mar 2025 |
| Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity | 12 Mar 2025 |
| Zealand Pharma Announces Financial Results for the Full Year 2024 | 20 Feb 2025 |
| Correction: Zealand Pharma Announces Financial Results for the Full Year 2024 | 20 Feb 2025 |
| Zealand Pharma convenes its Annual General Meeting 2025 | 20 Feb 2025 |
| Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | 13 Jan 2025 |